Quality of Life and Depression Symptoms After Therapy De-Escalation in HPV+ Oropharyngeal Squamous Cell Carcinoma
Authors:
- 4 April 2024
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 150 (5) , 429-435
Abstract
Importance Despite interest in therapy de-escalation for survivors of human papillomavirus–mediated oropharyngeal squamous cell carcinoma (HPV-positive OPSCC), the association of de-escalated therapy with patient-reported quality of life (QoL) outcomes and burden of depressive symptoms remains unclear. Objective To identify associations between clinicopathologic and therapeutic variables with patient-reported QoL outcomes and depression symptom burden in patients with HPV-positive OPSCC, who were enrolled in a therapy de-escalation trial. Design, Setting, and Participants In this nonrandomized controlled, open-label, curative-intent therapy de-escalation clinical trial in adults with stage I, II, and III HPV-positive OPSCC, patients were recruited from a high-volume head and neck oncology practice. Main Outcomes and Measures The main outcomes of this study included quantitative, patient-reported QoL and depression symptoms per well-validated inventories. Patient-reported QoL was based on Functional Assessment of Cancer Therapy–Head & Neck (FACT-HN) scores (range, 0-148; lower score indicates inferior QoL). Patient-reported depression-related symptom burden was based on Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR) scores (range, 0-27; a higher score indicates a higher burden of depression symptoms). Baseline clinicopathologic and treatment variables were paired with FACT-HN and QIDS-SR scores at baseline, 3, 6, 12, 24, and 36 months. Linear mixed-effect models with a random intercept were used for each participant and fixed effects for other measures. Regression coefficients are reported with 95% CIs. Results A total of 95 patients were followed up for a median (IQR) of 2.2 (1.6-3.2) years. Of these, 93 patients (98%) were male with a mean (SD) age of 60.5 (8.2) years. Overall, 54 participants (57%) had a history of current or former smoking, 47 (50%) underwent curative-intent surgery (with or without adjuvant therapy), and 48 (50%) underwent primary radiotherapy (with or without chemotherapy). The median (IQR) radiotherapy dose was 60 (60-70) Gy. Five deaths and 2 recurrence events were observed (mean [SD] recurrence interval, 1.4 [1.5] years). A higher radiotherapy dose was the only modifiable factor associated with inferior patient-reported QoL (lower FACT-HN) (coefficient, −0.66 [95% CI, −1.09 to −0.23]) and greater burden of depression-related symptoms (higher QIDS-SR) (coefficient, 0.11 [95% CI, 0.04-0.19]). With the 70-Gy dose as reference, improvements in FACT-HN and QIDS-SR scores were identified when patients received 51 to 60 Gy (coefficient, 12.75 [95% CI, 4.58-20.92] and −2.17 [−3.49 to −0.85], respectively) and 50 Gy or lower (coefficient, 15.03 [4.36-25.69] and −2.80 [−4.55 to −1.04]). Conclusions and Relevance In this nonrandomized controlled, open-label, curative-intent therapy de-escalation trial, a higher radiotherapy dose was associated with inferior patient-reported QoL and a greater burden of depression-related symptoms. This suggests opportunities for improved QoL outcomes and reduced depression symptom burden with a reduction in radiotherapy dose. Trial Registration ClinicalTrials.gov Identifier:NCT04638465Keywords
This publication has 27 references indexed in Scilit:
- Patient-Reported Symptom Severity, Health-Related Quality of Life, and Emotional Distress Trajectories During and After Radiation Therapy for Human Papillomavirus–Associated Oropharyngeal Cancer: A TROG 12.01 Secondary AnalysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2023
- Quality of life after radiation and transoral robotic surgery in advanced oropharyngeal cancerLaryngoscope Investigative Otolaryngology, 2021
- Factors associated with the quality of life for hospitalized patients with HPV-associated oropharyngeal squamous cell carcinomaOral Oncology, 2020
- Identification of Baseline Characteristics Associated With Development of Depression Among Patients With Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 2018
- Mature results of a prospective study of deintensified chemoradiotherapy for low‐risk human papillomavirus‐associated oropharyngeal squamous cell carcinomaCancer, 2018
- Patient‐reported quality‐of‐life outcomes after de‐escalated chemoradiation for human papillomavirus‐positive oropharyngeal carcinoma: Findings from a phase 2 trialCancer, 2017
- Oncologic outcomes and patient-reported quality of life in patients with oropharyngeal squamous cell carcinoma treated with definitive transoral robotic surgery versus definitive chemoradiationOral Oncology, 2016
- Prevention of Depression With Escitalopram in Patients Undergoing Treatment for Head and Neck CancerRandomized, Double-blind, Placebo-Controlled Clinical TrialEscitalopram for Depression PreventionJAMA Otolaryngology–Head & Neck Surgery, 2013
- The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depressionBiological Psychiatry, 2003
- The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale: A study of utility and validityCancer, 1996